Preoperative hydronephrosis predicts adverse pathological features and postoperative survival in patients with high-grade upper tract urothelial carcinoma

被引:2
作者
Qian, Subo [1 ]
Liang, Chengcai [2 ]
Ding, Yu [1 ]
Wang, Chen [1 ]
Shen, Haibo [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Urol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
[2] Sun Yat Sen Univ, Dept Gastr & Pancreat Surg, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China
来源
INTERNATIONAL BRAZ J UROL | 2021年 / 47卷 / 01期
关键词
Hydronephrosis; Nephroureterectomy; Urinary Tract; UPPER URINARY-TRACT; RADICAL NEPHROURETERECTOMY; ONCOLOGIC OUTCOMES; PROGNOSTIC-FACTORS; WORSE PROGNOSIS; CHEMOTHERAPY; NEOADJUVANT; ADJUVANT; TUMORS;
D O I
10.1590/S1677-5538.IBJU.2020.0021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Epidemiological studies reported conflicting results about preoperative hydronephrosis in upper tract urothelial carcinoma (UTUC). This study aimed to investigate the association between preoperative hydronephrosis and pathologic features and oncologic outcomes in patients with UTUC treated by radical nephroureterectomy (RNU). Materials and Methods: This was a retrospective, single-center cohort study of 377 patients treated by RNU without perioperative chemotherapy between January 2001 and December 2014. Logistic regression, Cox regression, and survival analyses were performed. Results: Among the 226 patients with high-grade UTUC, 132 (58%) had preoperative hydronephrosis. Multivariable logistic regression revealed that hydronephrosis was independently associated with advanced pT stage (P=0.017) and lymph node or lymphovascular invasion (P=0.002). Median follow-up was 36 months (interquartile range: 20-48 months). The 3- and 5-year overall survival (OS) rates in patients with hydronephrosis were significantly lower than in those without hydronephrosis (both P <0.001). The 3- and 5-year cancer-specific survival (CSS) rates in patients with hydronephrosis were significantly lower than in those without hydronephrosis (both P=0.001). Hydronephrosis was independently associated with OS and CSS (P=0.001 and P=0.004, respectively). Among the 151 patients with low-grade UTUC, hydronephrosis was not associated with pathologic features and postoperative survival. Conclusions: Preoperative hydronephrosis was significantly associated with adverse pathologic features and postoperative survival in patients with high-grade UTUC.
引用
收藏
页码:159 / 168
页数:10
相关论文
共 50 条
  • [41] High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients
    Ke, Hung-Lung
    Lin, Hui-Hui
    Li, Wei-Ming
    Li, Ching-Chia
    Chang, Lin-Li
    Lee, Yi-Chen
    Huang, Chun-Nung
    Wu, Wen-Jeng
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (08): : 2447 - 2454
  • [42] Urinary cytology with acridine orange fluorescence is highly valuable for predicting high-grade upper urinary tract urothelial carcinoma
    Li, Jing
    Zhang, Zhihong
    Wang, Jin
    Zhang, Changwen
    Li, Haibo
    Xu, Yong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (02): : 774 - 778
  • [43] The preoperative serum cystatin-C as an independent prognostic factor for survival n upper tract urothelial carcinoma
    Tan, Ping
    Shi, Ming
    Chen, Jie
    Xu, Hang
    Xie, Nan
    Xu, Huan
    Jiang, Yong
    Al, Jian-Zhong
    Liu, Liang-Ren
    Yang, Lu
    Wei, Qiang
    ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (02) : 163 - 169
  • [44] Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma
    Kir, Gozde
    Cecikoglu, Gozde Ecem
    Topal, Cumhur Selcuk
    Sorkun, Muhammet Huseyin
    Culpan, Meftun
    Suceken, Ferhat Yakup
    Karaca, Hakan
    Yildirim, Asif
    VIRCHOWS ARCHIV, 2023, 483 (05) : 621 - 634
  • [45] Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma
    Foerster, Beat
    Abufaraj, Mohammad
    Petros, Firas
    Azizi, Mounsif
    Gupta, Mohit
    Schweitzer, Donald
    Margulis, Vitaly
    Iwata, Takehiro
    Kimura, Shoji
    Shabsigh, Ahmad
    Briganti, Alberto
    Ku, Ja H.
    Muilwijk, Tim
    Kassouf, Wassim
    Matin, Surena F.
    Spiess, Philippe E.
    Pierorazio, Phillip M.
    Hendricksen, Kees
    Shariat, Shahrokh F.
    JOURNAL OF UROLOGY, 2020, 203 (06) : 1101 - 1108
  • [46] Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma
    Schmitz, Robin
    Mao, Rui
    Moris, Dimitrios
    Strickler, John H.
    Blazer, Dan, III
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (01) : 114 - 120
  • [47] Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?
    Ng, Casey K.
    Shariat, Shahrokh F.
    Lucas, Steven M.
    Bagrodia, Aditya
    Lotan, Yair
    Scherr, Douglas S.
    Raman, Jay D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (01) : 27 - 32
  • [48] Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma
    Wu, Yu-Peng
    Lin, Yun-Zhi
    Lin, Min-Yi
    Lin, Ting-Ting
    Chen, Shao-Hao
    Wei, Yong
    Zheng, Qing-Shui
    Xue, Xue-Yi
    Xu, Ning
    TUMORI JOURNAL, 2018, 104 (06): : 451 - 458
  • [49] Preoperative positive voided urine cytology predicts poor clinical outcomes in patients with upper tract urothelial carcinoma undergoing nephroureterectomy
    Wen Liu
    Zhankun Wang
    Shuai Liu
    Yu Yao
    Yong Liu
    Guiming Zhang
    BMC Cancer, 20
  • [50] Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma
    Ruvolo, Claudia Colla
    Nocera, Luigi
    Stolzenbach, L. Franziska
    Wenzel, Mike
    Cucchiara, Vito
    Tian, Zhe
    Shariat, Shahrokh F.
    Saad, Fred
    Longo, Nicola
    Montorsi, Francesco
    Briganti, Alberto
    Mirone, Vincenzo
    Karakiewicz, Pierre, I
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (05): : 792 - 801